Gyakorlatok spinális izomatrófiánál (SMA) — kezelés utáni era: fokozatos aerob + erő biztonságos (Montes 2019)

Mercuri 2018 + Finkel 2017 SMA care consensus framework. Spinal muscular atrophy is an autosomal-recessive disorder caused by SMN1 gene deletion or mutation, leading to motor neuron loss and progressive muscle weakness. Classification into Types 1-4 by age of onset and severity: Type 1 (Werdnig-Hoffmann) onset before 6 months, historically fatal by 2 years untreated; Type 2 onset 7-18 months, never walk independently; Type 3 (Kugelberg-Welander) onset >18 months, achieve ambulation; Type 4 adult onset, mildest. The treatment landscape was revolutionized 2017-2024: nusinersen (Spinraza, FDA 2016) intrathecal SMN2 splice modifier, onasemnogene abeparvovec (Zolgensma, FDA 2019) single-dose AAV9 gene therapy, risdiplam (Evrysdi, FDA 2020) oral small-molecule splice modifier. Treated infants now achieve milestones — sitting, standing, walking — that were previously impossible. The exercise framework evolved alongside: pre-treatment-era 'avoid all exercise to preserve motor neurons' has been replaced by Montes 2019 + Cerveró 2018 + Lewelt 2015 evidence that graded aerobic + light strength + aquatic + range-of-motion IS safe and IMPROVES function across all types and treatment statuses. AVOID exhaustion (the metabolic signature still matters); respiratory + bulbar care is non-negotiable across all types.

Volya's catalogue carries the foundation moves: supported-glute-bridge for posterior chain low-intensity work, cat-cow for spinal mobility, supine-knee-to-chest for low-back release + hip stretch, diaphragmatic-breathing as the central respiratory training (intercostal weakness makes the diaphragm even more critical in SMA), pursed-lip-breathing for dyspnea + respiratory muscle endurance, seated-march for cardio without joint impact (especially during ambulatory-to-non-ambulatory transition or for Types 1-2 from start), ankle-pump for circulation + distal-muscle ROM + DVT prevention, sit-to-stand for functional + bone-loading within ability + balance limits (Types 3-4 ambulatory), chin-tuck for cervical posture (neck weakness common across types). The AI coach also knows the nutrition side — caloric requirement varies dramatically by treatment status + type (pre-treatment Type 1 may need hypocaloric to prevent respiratory-exceeding overgrowth per Davis 2014; treated Type 1-2 may have NORMAL needs; Types 3-4 ambulatory may have CV + metabolic risk from reduced activity), type-specific feeding modality (NG → PEG → gastric vs jejunal per Standard of Care + Wang 2007 + Mercuri 2018 EARLY PEG when dysphagia compromises), protein 1.2-1.5 g/kg (1.0-1.2 severe), bone density Ca + vit D + weight-bearing within limits + DEXA, free fatty acid (FFA) elevation in Type 1 monitoring (Crawford 1999), KETOGENIC DIET AVOIDED in SMA (historical metabolic decompensation per Bowerman 2017), dysphagia + aspiration SLP critical across all types, respiratory BiPAP + cough assist, scoliosis 90%+ Types 2-3 post-surgical fusion nutrition, AVOID restrictive fad diets. CRITICAL: Cure SMA + MDA + TREAT-NMD + ProveR4 SMA + SMA Foundation + neurology (SMA-experienced, ideally certified center) + pulmonology + GI + SLP + orthopedics if scoliosis + dietitian familiar with SMA + family genetic counselling. This is NEVER a replacement for SMA-center multidisciplinary care.